Factor |
Telaprevir (n=46) |
Boceprevir (n=26) |
PEG/RBV (n=72) |
P |
HCV Mode of Transmission, n (%) |
|
|
|
|
IVDU |
13 (33.3) |
8 (40.0) |
25 (54.3) |
0.14 |
Blood transfusion |
13 (33.3) |
9 (45.0) |
22 (47.8) |
0.38 |
Tattoo |
5 (12.8) |
3 (15.0) |
9 (19.6) |
0.69 |
Cocaine |
2 (5.1) |
4 (20.0) |
7 (15.2) |
0.19 |
Health-care associated |
1 (2.6) |
1 (5.0) |
4 (8.7) |
0.47 |
Vertical Transmission |
3 (7.7) |
1 (5.0) |
0 (0.0) |
0.17 |
Fibrosis stage |
|
|
|
0.15 |
0 |
3 (7.3) |
6 (24.0) |
8 (11.4) |
|
1 |
5 (12.2) |
4 (16.0) |
12 (17.1) |
|
2 |
8 (19.5) |
3 (12.0) |
21 (30.0) |
|
3 |
12 (29.3) |
5 (20.0) |
16 (22.9) |
|
4 |
13 (31.7) |
7 (28.0) |
13 (18.6) |
|
Previous therapy with PEG/RBV, n (%) |
|
|
|
<0.001 |
Treatment naïve |
15 (36.6) |
11 (50.0) |
62 (92.5) |
|
Relapser |
16 (39.0) |
2 (9.1) |
2 (3.0) |
|
Partial responder |
6 (14.6) |
3 (13.6) |
2 (3.0) |
|
Null responder |
4 (9.8) |
6 (27.3) |
1 (1.5) |
|
Baseline ALT, U/L, mean (CI) |
68.0 (41.0, 100.0) |
71.0 (37.0, 99.0) |
66.0 (42.0, 94.0) |
0.96 |
Baseline AST, U/L, mean (CI) |
54.0 (35.0, 79.0) |
52.0 (41.0,87.0) |
56.0 (41.5,99.5) |
0.52 |
Baseline HCV RNA (×105), IU/mL, mean (CI) |
24.0 (8.1, 64.6) |
23.0 (9.4, 42.9) |
8.0 (3.6, 15.4) |
<0.001 |
Baseline Serum Creatinine, mg/dL, mean (SD) |
0.82 (0.20) |
0.81(0.25) |
0.92 (0.36) |
0.25 |
Baseline Hemoglobin, g/dL, mean (SD) |
14.8 (1.4) |
14.9 (1.2) |
14.9 (1.2) |
0.93 |
Interferon dose, n, (%) |
|
|
|
0.031 |
peg-interferon alfa-2a |
41(91.1)* |
21(80.8) |
48 (70.6)* |
|
peg-interferon alfa-2b |
4 (8.9) |
5 (19.2) |
20 (29.4) |
|
Values presented as Mean (Standard Deviation with Analysis of variance)
*Use of peg-interferon alfa-2a was significantly higher in Telaprevir arm as compared to PEG/RBV arm
Abbreviations: n=number of patients, CI=confidence interval, IVDU=Intravenous drug use, PEG=peg-interferon, RBV=ribavirin, ALT=alanine aminotransferase,
AST=aspartate aminotransferase, HCV=hepatitis C virus, U/L=units/Liter, IU/mL=International Units/milliliter, mg=milligram |